Gilead’s cell therapy Yescarta awarded FDA approval for follicular lymphoma March 8, 2021 Auto Bot BioPharma, biopharma nl, California, cancer immunotherapy, FDA, Follicular Lymphoma, Foster City, Gilead Sciences, Legal, Pharma 0 FDA approval for Yescarta in follicular lymphoma makes it the first approved CAR-T treatment for this type of cancer. It also marks Gilead Sciences’ third approved indication for a CAR-T cell therapy.